More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Dec 3 2009

Bristol-Myers Squibb Company (NYSE: BMY) today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51^st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.

Two oral presentations will feature data on the investigational use of SPRYCEL® (dasatinib) in patients with newly-diagnosed chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL). A third oral presentation will highlight data on elotuzumab, an investigational compound in development for patients with multiple myeloma. Elotuzumab is a humanized monoclonal antibody directed against a cell-surface glycoprotein called CS1.

“Bristol-Myers Squibb is committed to developing innovative medicines that address areas of significant unmet medical need such as CML, Ph(+) ALL and multiple myeloma,” said Renzo Canetta, M. D., vice president, Oncology Global Clinical Research, Bristol-Myers Squibb. “The data being presented at ASH from our portfolio of oncology assets underscore Bristol-Myers Squibb’s commitment to seeking advances in care for patients with hematological malignancies.”

Results from a Phase 2 trial evaluating the safety and efficacy of SPRYCEL in the treatment of newly-diagnosed CML patients, which was conducted by the University of Texas M.D. Anderson Cancer Center, will be the subject of one oral presentation. The abstract titled “Efficacy of Dasatinib in Patients with Previously Untreated CML in Early Chronic Phase” is scheduled for presentation on Monday, December 7, 2009 at 10:45 a.m.

Results from the ongoing international Phase 3 head-to-head clinical trial of SPRYCEL (100 mg once daily) vs. Gleevec^®* (imatinib; 400mg once daily) in the first-line treatment of CML are expected in the first half of 2010.

SPRYCEL data will also be featured in an oral presentation on newly-diagnosed Ph(+) ALL patients from a Phase 2 study conducted by M.D. Anderson Cancer Center. The abstract titled “Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia” will be presented on Tuesday, December 8, 2009 at 8:00 a.m..

The third oral presentation will highlight results from a Phase 1/2 study evaluating the potential of elotuzumab with lenalidomide and low dose dexamethasone in patients with relapsed or refractory multiple myeloma. The abstract titled “Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results” will be presented on Monday, December 7, 2009 at 11:45 a.m. Bristol-Myers Squibb is developing elotuzumab in collaboration with Facet Biotech Corporation.